To study the serum level of macrophage inflammatory protein-1α(MIP-1α) and interferon gamma inducible protein-10 (IP-10) in acute myelogenous leukemia (AML) and clarify their clinical significance.

Enzyme-linked immunosorbent assay was used to detect the level of MIP-1α and IP-10 in serum samples from 34 AML patients(observation group) and 20 volunteers (normal control group).

The levels of MIP-1α and IP-10 in observation group before induction chemotherapy were significantly higher than those in normal control group (P<0.05). The levels of MIP-1α and IP-10 in observation group after induction chemotherapy were decreased, and significantly lower than those before induction chemotherapy (P<0.05). After treatment for one course, 21 patients reached complete remission (CR), and 13 patients did not reach CR. The levels of MIP-1α and IP-10 in CR group had no significant difference compared with those in normal control group (P<0.05), but the levels of MIP-1α and IP-10 in none CR group were significantly higher than those in normal control group and CR group (P<0.05). The drop percentage of MIP-1αlevels in CR group and none CR group was (32.51 ± 10.34)% and (10.57 ± 10.39)%, and there was significant difference (P<0.05). The drop percentage of IP-10 levelsin CR group and none CR group was(45.94 ± 13.68)% and (31.17 ± 11.85)%, and there was significant difference (P<0.05). Liner correlation analysis revealed that the levels of MIP-1α and IP-10 had significantly positive correlation in AML patients (r = 0.652, P<0.05).

Different expressions of serum MIP-1α and IP-10 are found before and after induction chemotherapy AML patients, and there is significant correlation. Combined detection of serum MIP-1α and IP-10 may be used as an index to monitor clinical stages and prognosis.

Acute myelogenous leukemia; Macrophage inflammatory protein-1α; Interferon gamma inducible protein-10